NRx Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
The 8-K reports a material contract entered into on September 29, 2026, by NRx Defense Systems, Inc., a subsidiary of NRx Pharmaceuticals. The filing was signed October 5, 2026. This is an event filing, not a periodic financial report.
Financial and contract metrics
- DARPA contract aggregate value: approximately $11.2 million.
- Initially obligated funding: approximately $6.7 million. Further funding is contingent on appropriations and DARPA exercising funding options.
- Performance period: 18 months. Payments are tied to achievement and acceptance of specified milestones.
- The filing provides no revenue, earnings, cash flow, margin, debt, or liquidity results, and does not state how or when contract amounts will be recognized as revenue.
Material development and outlook
The contract funds the SPARC-TMS clinical trial, designed to evaluate a single-day protocol combining robotic neuro-navigated transcranial magnetic stimulation with NRX-101 for treatment-resistant depression. The filing says the trial has FDA approval and is expected to begin enrolling patients; it gives no enrollment start date or trial results.
NRx Defense generally retains ownership of inventions developed under the contract, subject to government rights. DARPA receives specified government-use rights in inventions and rights in certain technical data and software. The contract may be terminated in certain circumstances, including if the program is considered unlikely to meet its objectives.
Risks and contingencies
Additional contract funding is not assured and depends on appropriations and DARPA options. The filing also highlights risks related to clinical development and regulatory approval, manufacturing, competition, intellectual property, financing, and other matters described in the company’s SEC filings. The contract’s complete terms are to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026.
Key facts for investors to verify
- Whether DARPA obligates the remaining potential funding and exercises its funding options.
- Milestone requirements, acceptance conditions, and termination provisions in the complete contract.
- Patient-enrollment timing, trial progress, and any clinical results for SPARC-TMS.
- How the contract affects reported revenue, expenses, and cash flows in subsequent financial statements.